Jeffrey Zerillo Sells 1,207 Shares of Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

• On Tuesday, May 5th, Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $55.32, for a total transaction of $19,140.72.
• On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $52.53 on Friday. The company’s fifty day moving average price is $60.23 and its 200 day moving average price is $61.92. Prestige Consumer Healthcare Inc. has a 12 month low of $51.24 and a 12 month high of $89.37. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The firm has a market capitalization of $2.49 billion, a P/E ratio of 13.90, a P/E/G ratio of 1.64 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the business earned $1.22 earnings per share. Prestige Consumer Healthcare’s revenue was down 2.4% compared to the same quarter last year. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on PBH shares. Oppenheimer dropped their price objective on shares of Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating on the stock in a research note on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Finally, Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. UMB Bank n.a. increased its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the period. Bayforest Capital Ltd purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $29,000. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at about $32,000. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).